Federal Circuit Upholds Ruling Favoring Impax In Suit Over Wellbutrin, Zyban ANDAs
The court ruled that Impax’s generic product did not infringe GlaxoSmithKline’s U.S. patent for its antidepressant Wellbutrin SR.
The ruling, which stated that GlaxoSmithKline “cannot prove infringement literally or under the doctrine of equivalents,” upholds an earlier decision from the U.S. District Court for the Northern District of California.
GlaxoSmithKline markets Wellbutrin SR for...
To view the full article, register now.